
Anika Therapeutics (ANIK) Stock Forecast & Price Target
Anika Therapeutics (ANIK) Analyst Ratings
Bulls say
Anika Therapeutics reported a sequential growth of 40% in surgical procedures, indicating a robust increase in demand for its orthopedic products, particularly its innovative patch technology. The company's revenue reached $30.6 million, reflecting a 1.4% year-over-year increase when adjusted for recent divestitures, while international revenue from osteoarthritis pain management grew by 22% in the quarter. Additionally, Anika raised its free cash flow target from $50 million to over $125 million due to improved working capital and operational efficiencies, reinforcing a positive outlook for the company's financial health and growth potential.
Bears say
Anika Therapeutics Inc has shown disappointing financial guidance for FY/25, as management has materially reduced its adjusted EBITDA margin estimate from a previously anticipated double-digit margin to a range of 8-10%. This revision primarily stems from pricing weakness in the U.S. market for osteoarthritis pain management, which has negatively impacted revenue expectations. Additionally, the potential adverse effects of pandemics and changes in consumer sentiment could further hinder sales, prompting a reduction in the 2025 adjusted EBITDA estimate from $12.5 million to $9.3 million.
This aggregate rating is based on analysts' research of Anika Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Anika Therapeutics (ANIK) Analyst Forecast & Price Prediction
Start investing in Anika Therapeutics (ANIK)
Order type
Buy in
Order amount
Est. shares
0 shares